SG11201407546QA - Novel ring-substituted n-pyridinyl amides as kinase inhibitors - Google Patents
Novel ring-substituted n-pyridinyl amides as kinase inhibitorsInfo
- Publication number
- SG11201407546QA SG11201407546QA SG11201407546QA SG11201407546QA SG11201407546QA SG 11201407546Q A SG11201407546Q A SG 11201407546QA SG 11201407546Q A SG11201407546Q A SG 11201407546QA SG 11201407546Q A SG11201407546Q A SG 11201407546QA SG 11201407546Q A SG11201407546Q A SG 11201407546QA
- Authority
- SG
- Singapore
- Prior art keywords
- emeryville
- california
- diagnostics
- lllll
- international
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/175388 A1 (51) International Patent Classification: C07D 403/12 (2006.01) C07D 401/14 (2006.01) C07D 401/12 (2006.01) C07D 403/14 (2006.01) C07D 407/14 (2006.01) C07D 409/14 (2006.01) C07D 417/12 (2006.01) C07D 417/14 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/IB2013/054145 20 May 2013 (20.05.2013) English (30) Priority Data: 61/649,645 61/695,533 21 May 2012 (21.05.2012) 31 August 2012(31.08.2012) English US US (71) Applicant (for all designated States except US): NO- VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). (72) Inventors; and (71) Applicants (for US only): BURGER, Matthew [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). DRUMM III, Joseph [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608- 2916 USA (US). NISHIGUCHI, Gisele [US/US]; No vartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). RICO, Alice [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). SIMMONS, Robert Lowell [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). TAFT, Benjamin [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). TAN NER, Huw [GB/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608- 2916 (US). (74) Common Representative: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS H?N 00 00 m i> i-H (57) Abstract: The present invention provides compound a of formula (A): I as described herein, and pharmaceutically acceptable © salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating disease a or condition mediated CJ by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds. WO 2013/175388 A11 lllll llllllll II llllll III lllll lllll lllll lllll III III III lllll lllll lllll llll llll lllllll llll llll Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649645P | 2012-05-21 | 2012-05-21 | |
US201261695533P | 2012-08-31 | 2012-08-31 | |
PCT/IB2013/054145 WO2013175388A1 (en) | 2012-05-21 | 2013-05-20 | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407546QA true SG11201407546QA (en) | 2014-12-30 |
Family
ID=48699902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407546QA SG11201407546QA (en) | 2012-05-21 | 2013-05-20 | Novel ring-substituted n-pyridinyl amides as kinase inhibitors |
Country Status (27)
Country | Link |
---|---|
US (3) | US8987457B2 (en) |
EP (1) | EP2861585B1 (en) |
JP (2) | JP6204462B2 (en) |
KR (1) | KR20150013548A (en) |
CN (1) | CN104334546B (en) |
AP (1) | AP2014008046A0 (en) |
AR (1) | AR091117A1 (en) |
AU (1) | AU2013264831B2 (en) |
BR (1) | BR112014028954A2 (en) |
CA (1) | CA2873672A1 (en) |
CL (1) | CL2014003130A1 (en) |
CO (1) | CO7131360A2 (en) |
CR (1) | CR20140535A (en) |
DO (1) | DOP2014000265A (en) |
EA (1) | EA026432B1 (en) |
GT (1) | GT201400261A (en) |
HK (1) | HK1206021A1 (en) |
IL (1) | IL235747A0 (en) |
MX (1) | MX2014014253A (en) |
NI (1) | NI201400134A (en) |
PE (1) | PE20150194A1 (en) |
PH (1) | PH12014502586A1 (en) |
SG (1) | SG11201407546QA (en) |
TN (1) | TN2014000465A1 (en) |
TW (1) | TW201408641A (en) |
UY (1) | UY34818A (en) |
WO (1) | WO2013175388A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
US9453003B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
US9458151B2 (en) * | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
BR112014028954A2 (en) | 2012-05-21 | 2017-07-18 | Novartis Ag | ring-substituted n-pyridinyl amides as kinase inhibitors |
JP6437452B2 (en) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
DK2945939T3 (en) | 2013-01-15 | 2020-03-23 | Incyte Holdings Corp | THIAZOLIC CARBOXAMIDES AND PYRIDINE CARBOXAMIDE COMPOUNDS USED AS PIM KINASE INHIBITORS |
AR097431A1 (en) | 2013-08-23 | 2016-03-16 | Incyte Corp | FUR CARBOXAMIDE COMPOUNDS AND TIENOPIRIDINE USEFUL AS PIM KINASE INHIBITORS |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
AR105967A1 (en) | 2015-09-09 | 2017-11-29 | Incyte Corp | SALTS OF A PIM QUINASA INHIBITOR |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CA3095580A1 (en) | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251134A4 (en) | 2000-01-26 | 2003-01-29 | Meiji Seika Kaisha | Novel carbapenem derivatives of quaternary salt type |
AU2001231143A1 (en) * | 2000-01-27 | 2001-08-07 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
MXPA03008560A (en) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Single-stage pfc + ballast control circuit/general purpose power converter. |
CZ2004107A3 (en) | 2001-07-19 | 2004-04-14 | Pharmacia Italia S. P. A. | Phenylacetamido-thiazole derivatives, process of their preparation and their use as antineoplastic pharmaceutical compositions |
TW200424174A (en) * | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
KR100557093B1 (en) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | Tetrazole derivatives having inhibitory activity against multi-drug resistance and preparation thereof |
TW200523252A (en) | 2003-10-31 | 2005-07-16 | Takeda Pharmaceutical | Pyridine compounds |
JP2007513184A (en) | 2003-12-04 | 2007-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Quinoxaline useful as an inhibitor of protein kinase |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
US20060004197A1 (en) | 2004-07-02 | 2006-01-05 | Thomas Thrash | Sulfonamide-based compounds as protein tyrosine kinase inhibitors |
CA2574967A1 (en) | 2004-07-27 | 2006-02-09 | Sicor, Inc. | A process for the preparation of 7.alpha.-alkylated 19-norsteroids |
CR9465A (en) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | PHARMACOCINETICALLY IMPROVED COMPOUNDS |
CA2617532A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
WO2007044724A2 (en) | 2005-10-06 | 2007-04-19 | Exelixis, Inc. | Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3 |
JP5031760B2 (en) | 2005-11-10 | 2012-09-26 | シェーリング コーポレイション | Imidazopyrazine as a protein kinase inhibitor |
US8163746B2 (en) | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
CA2660560A1 (en) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
KR20090082440A (en) | 2006-10-31 | 2009-07-30 | 쉐링 코포레이션 | 2-amin0thiaz0le-4-carb0xylic amides as protein kinase inhibitors |
MX2009004786A (en) | 2006-10-31 | 2009-06-05 | Schering Corp | Anilinopiperazine derivatives and methods of use thereof. |
JP5103604B2 (en) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | 2-Aminothiazole-4-carboxylic acid amide as a protein kinase inhibitor |
CN101679266B (en) * | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | PIM kinase inhibitors and methods of their use |
AR067585A1 (en) | 2007-07-19 | 2009-10-14 | Schering Corp | AMIDAS HETEROCICLICAL COMPOUNDS AS INHIBITORS OF PROTEINCINASE |
AU2008299703C1 (en) | 2007-09-10 | 2013-09-05 | Cipla Limited | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process |
JP5507474B2 (en) | 2008-02-20 | 2014-05-28 | ノバルティス アーゲー | Heterocyclic inhibitors of stearoyl-CoA desaturase |
US20090221642A1 (en) | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
CN102015634B (en) | 2008-03-03 | 2014-02-12 | 陶氏益农公司 | Pesticides |
UA98698C2 (en) | 2008-03-03 | 2012-06-11 | Х. Луннбек А/С | Phenylsulfanylphenyl-piperidines and process for the preparation thereof |
FR2928151B1 (en) | 2008-03-03 | 2010-12-31 | Sanofi Aventis | N-HETEROCYCLIC PLATINUM-CARBENE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
US8168794B2 (en) * | 2008-03-03 | 2012-05-01 | Novartis Ag | Pim kinase inhibitors and methods of their use |
AR070531A1 (en) * | 2008-03-03 | 2010-04-14 | Novartis Ag | PIM KINASE INHIBITORS AND METHODS FOR USE |
PL2268618T3 (en) | 2008-03-03 | 2015-11-30 | Novartis Ag | Compounds and compositions as tlr activity modulators |
HUE026381T2 (en) | 2008-09-02 | 2016-06-28 | Novartis Ag | Picolinamide derivatives as kinase inhibitors |
WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
SG10201405568UA (en) * | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
BR112012025480A2 (en) | 2010-04-07 | 2020-08-18 | F. Hoffmann - La Roche Ag | compound, pharmaceutical composition composed of a compound, use of the compound and method of treating a disease or disorder |
CN103080106A (en) | 2010-07-06 | 2013-05-01 | 诺瓦提斯公司 | Cyclic ether compounds useful as kinase inhibitors |
CN103380117A (en) | 2011-01-21 | 2013-10-30 | Abbvie公司 | Picolinamide inhibitors of kinases |
UY33930A (en) * | 2011-03-04 | 2012-10-31 | Novartis Ag | NEW QUINASE INHIBITORS |
EP2681197A1 (en) | 2011-03-04 | 2014-01-08 | Novartis AG | Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
BR112014028954A2 (en) * | 2012-05-21 | 2017-07-18 | Novartis Ag | ring-substituted n-pyridinyl amides as kinase inhibitors |
-
2013
- 2013-05-20 BR BR112014028954A patent/BR112014028954A2/en not_active IP Right Cessation
- 2013-05-20 WO PCT/IB2013/054145 patent/WO2013175388A1/en active Application Filing
- 2013-05-20 KR KR1020147032346A patent/KR20150013548A/en not_active Application Discontinuation
- 2013-05-20 US US13/897,927 patent/US8987457B2/en active Active
- 2013-05-20 SG SG11201407546QA patent/SG11201407546QA/en unknown
- 2013-05-20 MX MX2014014253A patent/MX2014014253A/en unknown
- 2013-05-20 TW TW102117845A patent/TW201408641A/en unknown
- 2013-05-20 JP JP2015513327A patent/JP6204462B2/en active Active
- 2013-05-20 AP AP2014008046A patent/AP2014008046A0/en unknown
- 2013-05-20 CN CN201380026863.XA patent/CN104334546B/en active Active
- 2013-05-20 AU AU2013264831A patent/AU2013264831B2/en not_active Ceased
- 2013-05-20 US US14/402,541 patent/US9173883B2/en active Active
- 2013-05-20 EP EP13731958.8A patent/EP2861585B1/en active Active
- 2013-05-20 CA CA2873672A patent/CA2873672A1/en not_active Abandoned
- 2013-05-20 PE PE2014002041A patent/PE20150194A1/en not_active Application Discontinuation
- 2013-05-20 EA EA201492170A patent/EA026432B1/en not_active IP Right Cessation
- 2013-05-21 UY UY0001034818A patent/UY34818A/en not_active Application Discontinuation
- 2013-05-21 AR ARP130101768 patent/AR091117A1/en unknown
-
2014
- 2014-10-31 TN TN2014000465A patent/TN2014000465A1/en unknown
- 2014-11-17 IL IL235747A patent/IL235747A0/en unknown
- 2014-11-18 CL CL2014003130A patent/CL2014003130A1/en unknown
- 2014-11-20 CO CO14255686A patent/CO7131360A2/en unknown
- 2014-11-20 PH PH12014502586A patent/PH12014502586A1/en unknown
- 2014-11-20 NI NI201400134A patent/NI201400134A/en unknown
- 2014-11-21 CR CR20140535A patent/CR20140535A/en unknown
- 2014-11-21 GT GT201400261A patent/GT201400261A/en unknown
- 2014-11-21 DO DO2014000265A patent/DOP2014000265A/en unknown
-
2015
- 2015-02-12 US US14/620,649 patent/US20150150873A1/en not_active Abandoned
- 2015-07-10 HK HK15106597.7A patent/HK1206021A1/en unknown
-
2017
- 2017-08-31 JP JP2017167070A patent/JP2018048121A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804398XA (en) | Method for producing rna molecule compositions | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
SG11201408261UA (en) | Syringe | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201407867VA (en) | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists |